Fulgent Genetics (FLGT) Operating Expenses (2015 - 2026)

Fulgent Genetics has reported Operating Expenses for 12 years, with the latest figure at $61.8 million in Q2 2026.

• Quarterly Operating Expenses rose 14.04% year-over-year to $61.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $237.5 million (up 22.37% YoY) and the FY2025 annual result came in at $222.0 million, up 22.55% from the prior year.
• Operating Expenses climbed to $61.8 million in Q2 2026 per FLGT's latest filing, from $56.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $176.4 million in Q4 2023 and troughed at $39.6 million in Q3 2023.
• A 5-year average of $56.1 million and a median of $48.1 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses jumped 255.98% in 2023, then tumbled 72.79% in 2024.
• Over 5 years, Operating Expenses stood at $49.5 million in 2022, then surged by 255.98% to $176.4 million in 2023, then plunged by 72.79% to $48.0 million in 2024, then jumped by 43.42% to $68.8 million in 2025, then decreased by 10.27% to $61.8 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $61.8 million, $56.1 million, and $68.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.